Galderma Group AG

SWX:GALD Stock Report

Market Cap: CHF 23.5b

Galderma Group Valuation

Is GALD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GALD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
CHF 172.44
Fair Value
42.5% undervalued intrinsic discount
11
Number of Analysts

Below Fair Value: GALD (CHF99.1) is trading below our estimate of fair value (CHF172.44)

Significantly Below Fair Value: GALD is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GALD?

Key metric: As GALD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GALD. This is calculated by dividing GALD's market cap by their current earnings.
What is GALD's PE Ratio?
PE Ratio123.8x
EarningsUS$231.00m
Market CapUS$28.61b

Price to Earnings Ratio vs Peers

How does GALD's PE Ratio compare to its peers?

The above table shows the PE ratio for GALD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.5x
NOVN Novartis
17.2x6.2%CHF 182.1b
DESN Dottikon ES Holding
36.4xn/aCHF 2.7b
ROG Roche Holding
26.1x14.0%CHF 218.4b
COPN Cosmo Pharmaceuticals
6.3x-51.1%CHF 783.1m
GALD Galderma Group
123.8x31.1%CHF 23.5b

Price-To-Earnings vs Peers: GALD is expensive based on its Price-To-Earnings Ratio (123.8x) compared to the peer average (21.5x).

Price to Earnings Ratio vs Industry

How does GALD's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
GALD 123.8xIndustry Avg. 21.8xNo. of Companies9PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: GALD is expensive based on its Price-To-Earnings Ratio (123.8x) compared to the European Pharmaceuticals industry average (21.9x).

Price to Earnings Ratio vs Fair Ratio

What is GALD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GALD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio123.8x
Fair PE Ratio39.5x

Price-To-Earnings vs Fair Ratio: GALD is expensive based on its Price-To-Earnings Ratio (123.8x) compared to the estimated Fair Price-To-Earnings Ratio (39.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GALD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 99.10
CHF 107.44
+8.4%
7.9%CHF 115.57CHF 85.62n/a11
Apr ’26CHF 95.43
CHF 112.07
+17.4%
9.1%CHF 123.94CHF 85.93n/a11
Mar ’26CHF 109.94
CHF 108.76
-1.1%
11.0%CHF 128.06CHF 87.90n/a11
Feb ’26CHF 110.70
CHF 103.53
-6.5%
10.6%CHF 123.81CHF 84.51n/a11
Jan ’26CHF 100.64
CHF 99.84
-0.8%
7.9%CHF 109.53CHF 83.57n/a11
Dec ’25CHF 90.25
CHF 93.20
+3.3%
7.4%CHF 107.33CHF 80.47n/a11
Nov ’25CHF 81.44
CHF 89.47
+9.9%
7.9%CHF 105.52CHF 79.12n/a11
Oct ’25CHF 77.61
CHF 82.53
+6.3%
9.5%CHF 102.40CHF 72.86n/a11
Sep ’25CHF 82.30
CHF 79.93
-2.9%
7.6%CHF 90.06CHF 70.28n/a10
Aug ’25CHF 69.09
CHF 77.33
+11.9%
5.0%CHF 82.41CHF 71.02n/a8
Jul ’25CHF 72.11
CHF 78.75
+9.2%
4.8%CHF 83.81CHF 70.73n/a8
Jun ’25CHF 73.27
CHF 78.21
+6.7%
4.3%CHF 81.95CHF 71.43n/a7
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
CHF 107.44
Fair Value
7.8% undervalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/05 07:13
End of Day Share Price 2025/05/05 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Galderma Group AG is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Fulvio CazzolBerenberg
Bethan DaviesBerenberg
Victor FlochBNP Paribas Exane